On the heels of the premiere of its first-ever Spanish-language Cologuard campaign, Exact Sciences is doubling down on its ...

We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at ...

For colorectal cancer screening, colonoscopy and stool tests are more effective and less costly than novel first-generation ...

New analysis from the DETECT-A study supports MCED testing as a complement to current guideline-recommended screening in lung ...

At the beginning of October, the FDA approved the Cologuard Plus test, a next-generation, multitarget stool DNA test. While fecal testing is a good option for some patients, colonoscopy remains the ...

The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers ...

At the beginning of October, the FDA approved the Cologuard Plus test, a next-generation, multitarget stool DNA test approved for patients at an average risk for colorectal cancer. In a trial of ...

Amalgamated Bank reduced its stake in Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 2.8% in the 3rd quarter, ...

Exact Sciences Corporation EXAS has unveiled data highlighting significant advancements in the development of a multi-cancer early detection (MCED) test. The results of the DETECT-A (Detecting cancers ...

Exact Sciences' partnership with Ponce will help raise awareness among Hispanic adults about the importance of early detection through regular colon cancer screening, with the Cologuard ® test as a ...

Tucson, Ariz. (November 14, 2024) – The Tucson Conquistadores and the Cologuard Classic by Exact Sciences will host a two-night Concert Series Presented by Kaiser Garage Doors & Gates, IBM and ...

It developed Cologuard, a screening test for the early detection of colorectal cancer and pre-cancer. The company was founded on February 10, 1995 and is headquartered in Madison, WI.